Efficacy of Sindilizumab Combined with Platinum-containing Double-agent Chemotherapy in the Treatment of TP53 Mutated Non-small Cell Lung Cancer
Objective To investigate the efficacy of combination chemotherapy with sindilizumab and platinum-containing double-drug in the treatment of TP53 gene mutated non-small cell lung cancer.Methods A total of 72 non-small cell lung cancer patients with TP53 gene mutation admitted to Tongzhou District People's Hospital from March 2020 to February 2023 were selected as the study objects,and were divided into control group and observation group by random number table method,with 36 cases in each group.The control group was treated with platinum-containing double-drug chemotherapy,and the observation group was treated with sindillizumab + platinum-containing double-drug chemotherapy.The therapeutic efficacy,immunoglobulin index level,T cell subgroup index level,tumor marker level and adverse reactions of the two groups were compared.Results The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in immunoglobulin index,tumor labeling level and im-mune function index between 2 groups(all P>0.05).After treatment,immunoglobulin index and CD4+ in observation group were higher than those in control group,while tumor marker level and CD8+ in observation group were lower than those in control group,and the differences were statistically significant(all P<0.05).There was no significant dif-ference in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion The combination of sindilizumab and platinum-containing double-drug chemotherapy for non-small cell lung cancer with TP53 gene mu-tation can achieve a relatively ideal effect,which can not only improve the level of immune function,but also reduce the level of tumor markers,delay tumor development,and do not increase more adverse reactions.
NETL
NSTL
万方数据
维普
